Revenues from Sales

The company registered sales revenue of AED 1,024.1 million during the year 2011, a year-on-year (yoy) growth of 11.3% over sales of AED 920.2 million in the previous year.

Private Market vs. Tender Market Sales
Private market sales of AED 746.0 million saw a yoy growth of 28.7% and contributed 72.8% of the total sales, as against 63.0% in the previous year. As against this, the tender market sales of AED 278.1 million declined by 18.4% yoy, contributing 27.2% of the total sales, as against 37.0% during the previous year.

Our private market sales grew by about 29% during the year, boosted by increasingly diverse range of our products

Country-wise Sales
Saudi Arabia, with a contribution of 32.6% continued to be the leading market for Julphar’s products during the year. It was followed by UAE (12.0%), Iraq (11.4%), Lebanon (6.9%), Afghanistan (5.3%), Egypt (4.6%) and Kuwait (4.1%). The top-7 markets, thus, accounted for about 77% of the total sales for the year.

 

Significant gains were registered in many of our leading markets during the year, where Julphar further consolidated its market leadership position. UAE, Lebanon, Iraq, Egypt, Sudan and Oman were among our leading markets which saw huge gains for the company during the year under review. KSA, on the other hand saw a substantial decline in the tender market sales, off set to a certain extent by a strong growth in the private market sales.

We continued to build on our strong market presence. Sales growth was strong in all our major therapeutic segments during the year

Therapeutic Segment-wise Sales
Anti-infectives continued to be Julphar’s leading products. Products sold in this segment alone accounted for about a third of the company’s sales for the year. This was followed by oral cavity & gastrointestinal tract (15.0%. share), nutrition & blood (13.9%), skin (13.2%) and respiratory system (7.0%), respectively. The top-5 segments collectively accounted for about 82% of the total sales for the year, almost at the same level as in the previous year.

The company saw gains in most of its major therapeutic segments. Sales in nutrition & blood, skin, central nervous system, cardiovascular system and endocrine system witnessed strong growth during the year.

 

Order Book
Total Orders
The company continued to have a healthy order book at the end of the year, constituting both the private market and tender market orders.